Does the media refer more to XENE or MRNA?

In the previous week, Moderna had 19 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 25 mentions for Moderna and 6 mentions for Xenon Pharmaceuticals. Moderna's average media sentiment score of 0.49 beat Xenon Pharmaceuticals' score of 0.42 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 12 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral

Does the media refer more to XENE or VTRS?

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 4 mentions for Viatris. Viatris' average media sentiment score of 0.77 beat Xenon Pharmaceuticals' score of 0.42 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XENE or GMAB?

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 3 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Xenon Pharmaceuticals' score of 0.42 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XENE or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 6 mentions for Xenon Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Xenon Pharmaceuticals' score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is XENE or SMMT more profitable?

Xenon Pharmaceuticals' return on equity of -49.23% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -49.23% -46.42% Summit Therapeutics N/A -291.24% -243.07%

Does the media refer more to XENE or SMMT?

In the previous week, Summit Therapeutics had 11 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 17 mentions for Summit Therapeutics and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.42 beat Summit Therapeutics' score of 0.37 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Xenon Pharmaceuticals (XENE) Competitors

$52.79 +1.58 (+3.09%)

Closing price 04:00 PM Eastern

Extended Trading

$52.78 -0.01 (-0.01%)

As of 04:10 PM Eastern

Compare

XENE vs. MRNA, VTRS, GMAB, ASND, and SMMT

Should you buy Xenon Pharmaceuticals stock or one of its competitors? MarketBeat compares Xenon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xenon Pharmaceuticals include Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Xenon Pharmaceuticals compare to Moderna?

Xenon Pharmaceuticals (NASDAQ:XENE) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Xenon Pharmaceuticals currently has a consensus price target of $77.20, suggesting a potential upside of 46.24%. Moderna has a consensus price target of $36.60, suggesting a potential downside of 23.32%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Xenon Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Xenon Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 19 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 25 mentions for Moderna and 6 mentions for Xenon Pharmaceuticals. Moderna's average media sentiment score of 0.49 beat Xenon Pharmaceuticals' score of 0.42 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	12 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xenon Pharmaceuticals has higher earnings, but lower revenue than Moderna. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
Moderna	$1.94B	9.74	-$2.82B	-$8.15	N/A

Summary

Xenon Pharmaceuticals beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Viatris?

Xenon Pharmaceuticals (NASDAQ:XENE) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Viatris	-2.04%	19.04%	7.62%

Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Xenon Pharmaceuticals presently has a consensus target price of $77.20, suggesting a potential upside of 46.24%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 8.02%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Xenon Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xenon Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
Viatris	$14.30B	1.32	-$3.51B	-$0.26	N/A

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 4 mentions for Viatris. Viatris' average media sentiment score of 0.77 beat Xenon Pharmaceuticals' score of 0.42 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats Viatris on 11 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Genmab A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Xenon Pharmaceuticals currently has a consensus price target of $77.20, suggesting a potential upside of 46.24%. Genmab A/S has a consensus price target of $37.93, suggesting a potential upside of 51.11%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
Genmab A/S	$3.72B	4.21	$963M	$1.32	19.02

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 3 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Xenon Pharmaceuticals' score of 0.42 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Xenon Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Genmab A/S	21.05%	15.34%	8.94%

Summary

Genmab A/S beats Xenon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Xenon Pharmaceuticals currently has a consensus price target of $77.20, indicating a potential upside of 46.24%. Ascendis Pharma A/S has a consensus price target of $295.39, indicating a potential upside of 38.53%. Given Xenon Pharmaceuticals' higher probable upside, research analysts clearly believe Xenon Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 6 mentions for Xenon Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Xenon Pharmaceuticals' score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
Ascendis Pharma A/S	$814.57M	16.33	-$258M	$8.67	24.59

Ascendis Pharma A/S has a net margin of 57.87% compared to Xenon Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Xenon Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Xenon Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Xenon Pharmaceuticals (NASDAQ:XENE) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Summit Therapeutics had 11 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 17 mentions for Summit Therapeutics and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.42 beat Summit Therapeutics' score of 0.37 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xenon Pharmaceuticals presently has a consensus target price of $77.20, suggesting a potential upside of 46.24%. Summit Therapeutics has a consensus target price of $26.05, suggesting a potential upside of 82.32%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Xenon Pharmaceuticals' return on equity of -49.23% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Summit Therapeutics	N/A	-291.24%	-243.07%

Xenon Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market.

Xenon Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Summary

Xenon Pharmaceuticals beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Xenon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XENE vs. The Competition

Export

Metric	Xenon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.95B	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-11.23	18.68	24.75	23.76
Price / Sales	680.43	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	7.01	8.06	10.47	6.72
Net Income	-$345.91M	$23.83M	$3.56B	$337.35M
7 Day Performance	0.94%	-2.82%	-1.11%	-2.54%
1 Month Performance	-6.47%	2.22%	1.28%	1.42%
1 Year Performance	67.85%	37.70%	21.20%	24.71%

Xenon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XENE Xenon Pharmaceuticals	3.5405 of 5 stars	$52.79 +3.1%	$77.20 +46.2%	+61.9%	$4.95B	$7.50M	N/A	210
MRNA Moderna	1.3947 of 5 stars	$46.06 -2.4%	$35.73 -22.4%	+73.3%	$18.72B	$2.20B	N/A	4,700	Trending News Analyst Forecast Insider Trade
VTRS Viatris	2.9424 of 5 stars	$15.81 -2.8%	$16.43 +3.9%	+82.9%	$18.41B	$14.56B	N/A	30,000	Positive News
GMAB Genmab A/S	4.4683 of 5 stars	$25.45 -3.3%	$37.93 +49.0%	+11.7%	$16.42B	$3.72B	19.28	3,029	Gap Down
ASND Ascendis Pharma A/S	4.5542 of 5 stars	$218.82 -2.4%	$295.39 +35.0%	+18.9%	$13.98B	$865.78M	25.24	1,189	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XENE) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. MRNA, VTRS, GMAB, ASND, and SMMT

How does Xenon Pharmaceuticals compare to Moderna?

Summary

How does Xenon Pharmaceuticals compare to Viatris?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. MRNA, VTRS, GMAB, ASND, and SMMT

How does Xenon Pharmaceuticals compare to Moderna?

Which has more risk & volatility, XENE or MRNA?

Do analysts recommend XENE or MRNA?

Is XENE or MRNA more profitable?

Does the media refer more to XENE or MRNA?

Do insiders and institutionals have more ownership in XENE or MRNA?

Which has higher valuation & earnings, XENE or MRNA?

Summary

How does Xenon Pharmaceuticals compare to Viatris?

Is XENE or VTRS more profitable?

Which has more volatility & risk, XENE or VTRS?

Do insiders & institutionals hold more shares of XENE or VTRS?

Do analysts recommend XENE or VTRS?

Which has preferable earnings and valuation, XENE or VTRS?

Does the media refer more to XENE or VTRS?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Do institutionals and insiders hold more shares of XENE or GMAB?

Do analysts recommend XENE or GMAB?

Which has more volatility and risk, XENE or GMAB?

Which has stronger valuation and earnings, XENE or GMAB?

Does the media refer more to XENE or GMAB?

Is XENE or GMAB more profitable?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Do analysts rate XENE or ASND?

Does the media refer more to XENE or ASND?

Which has better valuation and earnings, XENE or ASND?

Is XENE or ASND more profitable?

Which has more risk & volatility, XENE or ASND?

Do institutionals and insiders have more ownership in XENE or ASND?

Summary

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Do insiders and institutionals have more ownership in XENE or SMMT?

Does the media refer more to XENE or SMMT?

Do analysts rate XENE or SMMT?

Is XENE or SMMT more profitable?

Which has more volatility & risk, XENE or SMMT?

Which has higher earnings & valuation, XENE or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools